Trial Profile
A randomized phase 2 double-blind, placebo-controlled study of GK-001 in hepatocellular carcinoma (HCC) in chronic hepatitis C patients after prior curative HCC treatment.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2012
Price :
$35
*
At a glance
- Drugs Rifampicin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors GeneCare Research Institute
- 02 Aug 2011 New trial record